We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
+9.34%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$612M
AUM Growth
+$115M
(+23%)
Cap. Flow
+$88.3M
Cap. Flow
% of AUM
14.44%
Top 10 Holdings %
Top 10 Hldgs %
8.98%
Holding
532
New
97
Increased
238
Reduced
88
Closed
80
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Telecom Argentina
TEO
|
+$2.03M |
| 2 |
Methanex
MEOH
|
+$1.43M |
| 3 |
EQM
EQM Midstream Partners, LP
EQM
|
+$1.32M |
| 4 |
Carlyle Secured Lending
CGBD
|
+$1.31M |
| 5 |
The GEO Group
GEO
|
+$1.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Oxford Square Capital
OXSQ
|
+$2.73M |
| 2 |
MPLX
MPLX
|
+$1.51M |
| 3 |
MDCO
Medicines Co
MDCO
|
+$982K |
| 4 |
Gladstone Investment Corp
GAIN
|
+$857K |
| 5 |
CELG
Celgene Corp
CELG
|
+$712K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 20.46% |
| 2 | Real Estate | 16.88% |
| 3 | Energy | 14.34% |
| 4 | Healthcare | 10.85% |
| 5 | Materials | 9.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
GTHX
226
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
| $441K | 0.07% |
16,684
+3,081
| +23% | +$72.1K |
|
227
Atara Biotherapeutics
ATRA
$71.2M
| $439K | 0.07% |
1,067
+605
| +131% | +$209K |
|
|
AGEN
228
Agenus
AGEN
$249M
| $437K | 0.07% |
5,466
+627
| +13% | +$42.1K |
|
229
Iovance Biotherapeutics
IOVA
$2.23B
| $436K | 0.07% |
15,764
+2,539
| +19% | +$57.8K |
|
|
AKRO
230
DELISTED
Akero Therapeutics
AKRO
| $433K | 0.07% |
+19,531
| New | +$404K |
|
231
Moderna
MRNA
$21.5B
| $433K | 0.07% |
22,133
+5,736
| +35% | +$102K |
|
|
ATNX
232
DELISTED
Athenex, Inc. Common Stock
ATNX
| $432K | 0.07% |
1,416
+706
| +99% | +$187K |
|
|
AUTL
233
Autolus Therapeutics
AUTL
$386M
| $430K | 0.07% |
32,577
+16,179
| +99% | +$212K |
|
234
Fate Therapeutics
FATE
$281M
| $429K | 0.07% |
21,917
+7,741
| +55% | +$123K |
|
235
Rocket Pharmaceuticals
RCKT
$348M
| $428K | 0.07% |
18,806
+3,143
| +20% | +$52.5K |
|
|
BHVN
236
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $428K | 0.07% |
7,860
+3,834
| +95% | +$190K |
|
237
Voyager Therapeutics
VYGR
$187M
| $427K | 0.07% |
30,608
+20,178
| +193% | +$293K |
|
238
AnaptysBio
ANAB
$1.6B
| $426K | 0.07% |
26,186
+22,566
| +623% | +$534K |
|
|
MYOV
239
DELISTED
Myovant Sciences Ltd.
MYOV
| $425K | 0.07% |
27,369
-1,811
| -6% | -$18.3K |
|
240
MacroGenics
MGNX
$235M
| $423K | 0.07% |
38,905
+22,311
| +134% | +$221K |
|
|
IMMU
241
DELISTED
Immunomedics Inc
IMMU
| $422K | 0.07% |
19,925
-523
| -3% | -$9.23K |
|
|
PGNX
242
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| $419K | 0.07% |
82,233
+20,460
| +33% | +$108K |
|
243
Viking Therapeutics
VKTX
$4.04B
| $416K | 0.07% |
51,823
+19,672
| +61% | +$143K |
|
244
Q32 Bio
QTTB
$450M
| $412K | 0.07% |
+1,106
| New | +$317K |
|
245
Cytokinetics
CYTK
$11B
| $410K | 0.07% |
38,686
+12,199
| +46% | +$125K |
|
|
RARX
246
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
| $410K | 0.07% |
8,735
-3,146
| -26% | -$139K |
|
247
Akebia Therapeutics
AKBA
$327M
| $407K | 0.07% |
64,476
+2,846
| +5% | +$13.5K |
|
|
RETA
248
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $407K | 0.07% |
1,992
-1,109
| -36% | -$202K |
|
|
YMAB
249
DELISTED
Y-mAbs Therapeutics
YMAB
| $406K | 0.07% |
+13,003
| New | +$385K |
|
|
SGMO
250
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $405K | 0.07% |
48,408
+21,277
| +78% | +$196K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
GC
ALS
Virtus ETF Advisers's Q4 2019 Portfolio in Review
As of Q4 2019, Virtus ETF Advisers held 532 positions worth $612M, up 23% from $496M the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Virtus ETF Advisers deployed $88.3M of net new capital in Q4 2019, opening 97 new positions and adding to 238 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 14,229 shares worth $462K.
By sector, the portfolio is most concentrated in Financials at 20% of assets, down from 24% a quarter earlier, followed by Real Estate and Energy.
On the sell side, the largest reduction was Oxford Square Capital, an estimated $2.73M trimmed.
- Virtus ETF Advisers's largest Q4 2019 buy was Odonate Therapeutics, Inc. Common Stock: 14,229 shares worth $462K.
- Virtus ETF Advisers added most to Telecom Argentina in Q4 2019, an estimated $2.03M increase.
- Virtus ETF Advisers's biggest Q4 2019 reduction was Oxford Square Capital, cutting an estimated $2.73M.
- Virtus ETF Advisers fully exited Medicines Co in Q4 2019, selling an estimated $982K.
- Virtus ETF Advisers's ten largest holdings make up 9% of its $612M portfolio in Q4 2019.
- Virtus ETF Advisers opened 97 new positions and closed 80 in Q4 2019.
- Virtus ETF Advisers's portfolio value rose 23% quarter-over-quarter to $612M.
Based on Virtus ETF Advisers's 13F filing for Q4 2019, filed 13 Feb 2020.